Parexel Sustainability Profile
Parexel International Corporation, commonly known as Parexel, is a leading global biopharmaceutical services provider headquartered in the United States. Founded in 1983, the company has established a strong presence in key operational regions, including Europe and Asia, delivering innovative solutions across the clinical research and regulatory consulting sectors. Specialising in drug development and regulatory affairs, Parexel offers a comprehensive suite of services that includes clinical trial management, biostatistics, and market access strategies. What sets Parexel apart is its commitment to advancing the development of new therapies while ensuring compliance with regulatory standards. With a robust market position, Parexel has achieved numerous milestones, including recognition for its excellence in clinical research. The company continues to play a pivotal role in the biopharmaceutical industry, helping clients navigate the complexities of bringing new drugs to market efficiently and effectively.
DitchCarbon Score
How does Parexel's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Parexel's score of 68 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Parexel's reported carbon emissions
In 2024, Parexel International Corporation reported total carbon emissions of approximately 323,408,000 kg CO2e. This figure includes 2,705,000 kg CO2e from Scope 1 emissions, 5,930,000 kg CO2e from Scope 2 emissions (location-based), and a significant 314,773,000 kg CO2e from Scope 3 emissions. The total emissions for 2023 were about 298,365,000 kg CO2e, with Scope 1 at 2,898,000 kg CO2e, Scope 2 at 6,969,000 kg CO2e, and Scope 3 at 288,498,000 kg CO2e. Parexel has set ambitious reduction targets, committing to a 42% reduction in absolute Scope 1 emissions by 2030 from a 2022 baseline. Additionally, the company aims to reduce its absolute Scope 3 emissions by 25% by the same year. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to sourcing 100% renewable electricity through 2030. The company’s emissions data is not cascaded from any parent organisation, indicating that these figures are independently reported by Parexel International Corporation. The ongoing efforts to reduce emissions demonstrate a proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 15,510,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 11,632,000 | 00,000,000 | 0,000,000 | - | - | - |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Parexel's Industry?
How Carbon Intensive is Parexel's Location?
Parexel's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Parexel has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Syneos Health
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
Frequently Asked Questions
Common questions about Parexel's sustainability data and climate commitments